Tirzepatide LinkPen – 10mg/3mL (300 Units) Prefilled Microdose Pen

The Tirzepatide LinkPen delivers 10mg of Tirzepatide in a 3mL (300-unit) prefilled pen designed for ultra-precise daily microdosing. Tirzepatide is a dual GIP and GLP-1 receptor agonist, clinically shown to surpass Semaglutide in fat loss and glucose management. Daily microdosing allows for superior control, gentler onset, and improved side effect profile.

This format is ideal for those seeking cutting-edge fat loss protocols, diabetic support, or enhanced insulin sensitivity—without the harsh peaks of weekly injections.

⚖️ Why Daily Microdosing?

• Gradual appetite suppression with fewer side effects (less nausea/bloating)
• Improved insulin sensitivity and glucose control
• More consistent fat-burning and metabolic effects
• ⏱️ Faster adjustment phase vs. large weekly jumps in dose
• Flexible titration: fine-tune daily dose with ease

Product Specs

Dosing Protocol (Daily Microdosing)

• Pen Volume: 300 total units (3mL at 10mg Tirzepatide)
• Recommended Starting Dose: 10 units per day (≈333mcg)
• Titration: Increase by 2–5 units weekly depending on response
• Common Range: 10–30 units/day (≈333mcg–1mg)
• Pen Duration: 10–30 days depending on daily dose
• Injection Route: Subcutaneous (abdomen or thigh preferred)

Benefits of Tirzepatide

• Rapid fat loss with appetite and craving control
• Dual action improves insulin sensitivity and glucose disposal
• Supports focus and reduced food impulse behavior
• Can be effective for both diabetic and non-diabetic users
• Clinically shown to outperform Semaglutide in bodyweight reduction

Stack Recommendations

• Accelerated Fat Loss: Combine with Tesofensine or BAM15
• Hormonal Balance: Add CJC-1295/Ipamorelin or low-dose TRT
• Insulin Optimization: Stack with Berberine, ALA, or MOTS-c

Storage & Use

• Store unopened pens in refrigerator (2–8°C / 36–46°F)
• ️ After first use, may be kept at room temperature up to 30 days
• Administer subcutaneously with fine insulin syringe or compatible pen tip

⚠️ Warnings & Considerations

• ⚠️ Not for use in individuals with history of medullary thyroid cancer or MEN2
• Possible mild side effects include nausea, delayed gastric emptying, or fatigue
• Do not combine with insulin or GLP-1s unless advised by a healthcare professional
• Not for individuals under the age of 21

Legal Disclaimer

This product is sold for research and educational purposes only. It is not approved by the FDA to diagnose, treat, or cure any condition. All information is for informational use only. By purchasing, you agree to use this compound in accordance with applicable laws and assume full responsibility for its use.